IMMULITE 2000 XPI ANTI-HBC

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P010051

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the immulite anti-hbc and immulite 2000 anti-hbc. These devices are indicated for: immulite. Anti-hbc: immulite anti-hbc is a solid -phase chemiluminescent enzyme immunoassay designed for use on the immulite automated immunoassay analyzer for the qualitative detection of total antibodies against hepatitis b core antigen (anti-hbc) in human serum or plasma (edta, heparinized, citrate). It is intended for in vitro diagnostic use for the laboratory diagnosis of ongoing or previous hepatitis b virus infection. Immulite. 2000 anti-hbc: immulite 2000 anti-hbc is a solid-phase chemiluminescent enzyme immunoassay designed for use on the immulite 2000 automated immunoassay analyzer for the qualitative detection of total antibodies against hepatitis b core antigen (anti-hbc) in human serum or plasma (edta, heparinized, citrate). It is intended for in vitro diagnostic use for the laboratory diagnosis of ongoing or previous hepatitis b virus infection.

DeviceIMMULITE 2000 XPI ANTI-HBC
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantSiemens Healthcare Diagnostics Products, LTD
Date Received2001-08-31
Decision Date2002-07-24
Notice Date2003-06-24
PMAP010051
SupplementS
Product CodeLOM
Docket Number03M-0271
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address Siemens Healthcare Diagnostics Products, LTD glyn Rhonwy llanberis, Caernarfon LL55
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P010051Original Filing
S017 2022-09-15 30-day Notice
S016
S015 2022-02-28 30-day Notice
S014 2020-12-22 Real-time Process
S013 2020-08-12 30-day Notice
S012 2019-11-25 30-day Notice
S011 2011-12-19 135 Review Track For 30-day Notice
S010 2011-08-16 30-day Notice
S009 2011-08-08 30-day Notice
S008 2011-02-18 Real-time Process
S007 2009-11-02 Normal 180 Day Track No User Fee
S006
S005 2008-11-10 Normal 180 Day Track No User Fee
S004 2005-12-22 Real-time Process
S003 2005-08-17 Special (immediate Track)
S002
S001 2002-11-20 Real-time Process

NIH GUDID Devices

Device IDPMASupp
00630414970981 P010051 001
00630414970974 P010051 001

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.